FF2049
FF2049 is a selective HDAC1-3 PROTAC degrader (with a DC50 of 257 nM against HDAC1). FF2049 recruits the E3 ligase FEM1B to mediate ubiquitination and proteasomal degradation of HDAC1-3. FF2049 induces cell cycle arrest and Apoptosis in cells. FF2049 can be used in research related to multiple myeloma, acute monocytic leukemia, triple-negative breast cancer and glioblastoma.
(Pink: HDAC ligand (HY-168864); Blue: FEM1B ligand (HY-168865); Black: linker (HY-Y0966)).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C31H38ClN7O7
- Molecular Weight:656.13
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle PROTACs Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
HDAC1 257 nM (DC50) |
HDAC2 |
HDAC3 |
In Vitro
FF2049 (90 min) potently inhibits recombinant HDAC1, HDAC2 and HDAC6 enzymes, with IC50 values of 0.074 μM, 0.156 μM and 0.009 μM, respectively; it shows weak inhibitory activity against HDAC4, with an IC50 of 13.3 μM[1].
FF2049 (2.5-25000 nM; 24 h) induces potent, concentration-dependent HDAC1 degradation in MM.1S cells via a FEM1B-, HDAC1- and neddylation-dependent mechanism, with a DC50 of 257 nM and a D_max of 85.2%, while leaving HDAC6 levels unaffected[1].
FF2049 (1 μM; 24 h) selectively degrades HDAC1, HDAC2 and HDAC3 in MM.1S cells without affecting other tested HDAC isoforms; it also exhibits strong cellular target-binding capacity, as evidenced by increased hyperacetylation levels of histone H3 and α-tubulin[1].
FF2049 (0.5 μM; 6 h) significantly induces the degradation of HDAC1 and HDAC2 in MM.1S cells, accompanied by the degradation of associated multi-subunit complex proteins (KDM1A, RCOR1, RCOR3, SIN3A, NCOR1, MIER1)[1].
FF2049 (10 μM; 24 h) induces significant HDAC1 degradation in MV4-11 (87%), MDA-MB-231 (53%) and U-87MG (75%) cells, confirming its activity against various cancer cell types[1].
FF2049 (71-72 h) exhibits antiproliferative activity against MM.1S (EC50 2.33 μM), MV4-11 (EC50 0.958 μM), MDA-MB-231 (EC50 26.5 μM) and U-87MG (EC50 37.4 μM) cells[1].
FF2049 (10 μM; 48 h) induces cell cycle arrest and apoptosis in MM.1S cells, which is evidenced by the decreased proportion of cells in S phase and increased proportion of cells in sub-G1 phase after treatment with 10 μM FF2049 for 48 h[1].
FF2049 (10 μM; 48 h) significantly induces early and late apoptosis in MM.1S cells after treatment at 10 μM for 48 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human multiple myeloma MM.1S cells
-
Concentration:2.5-25000 nM (24 h incubation); 1 μM (24 h incubation); 1 μM (6 h incubation with pre-treatment)
-
Incubation Time:24 h; 6 h (with 30 min pre-incubation for co-treatment groups)
-
Result:Induced concentration-dependent HDAC1 degradation with a half-maximal degradation concentration (DC50) of 257 nM and a maximal degradation (D_max) of 85.2% after 24 h treatment.
Induced 62.3% degradation of HDAC1 at 1 μM for 24 h, while HDAC6 levels remained largely unaffected.
Blocked HDAC1 degradation by co-treatment with the non-degrading control 1g-nc, the neddylation inhibitor MLN4924, or the HDAC inhibitor vorinostat.
-
Cell Line:human multiple myeloma MM.1S cells
-
Concentration:1 μM
-
Incubation Time:24 h
-
Result:Induced strong degradation of HDAC1, HDAC2, and HDAC3, while HDAC4, HDAC6, and HDAC8 levels remained unaffected.
Increased hyperacetylation of histone H3 (a marker of class I HDAC inhibition/degradation) and α-tubulin (a marker of HDAC6 inhibition) compared to vehicle control.
-
Cell Line:human acute monocytic leukemia MV4-11 cells, human triple-negative breast cancer MDA-MB-231 cells, human glioblastoma U-87MG cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Induced 87% HDAC1 degradation in MV4-11 cells.
Induced 53% HDAC1 degradation in MDA-MB-231 cells.
Induced 75% HDAC1 degradation in U-87MG cells.
The non-degrading control 1g-nc did not affect HDAC1 levels in any cell line.
-
Cell Line:human multiple myeloma MM.1S cells, human acute monocytic leukemia MV4-11 cells, human triple-negative breast cancer MDA-MB-231 cells, human glioblastoma U-87MG cells
-
Concentration:Increasing concentrations
-
Incubation Time:72 h (MM.1S, MV4-11); 71 h (MDA-MB-231, U-87MG)
-
Result:Exhibited antiproliferative activity with an EC50 of 2.33 μM in MM.1S cells.
Exhibited antiproliferative activity with an EC50 of 0.958 μM in MV4-11 cells.
Exhibited antiproliferative activity with an EC50 of 26.5 μM in MDA-MB-231 cells.
Exhibited antiproliferative activity with an EC50 of 37.4 μM in U-87MG cells.
-
Cell Line:human multiple myeloma MM.1S cells
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Induced a significant increase in both early and late apoptotic cell populations compared to vehicle control.
Chemical Information
-
Molecular Weight 656.13
-
Formel C31H38ClN7O7
-
SMILES
ONC(CCCCCCNC(C1=CC=C(C=C1)NC(CNC(CN2CCOC3=C2C=CC(N(C(CCl)=O)CCC#N)=C3)=O)=O)=O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Reinheit & Dokumentation
Verweise
[1]. Feller F, et al. Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders. Journal of medicinal chemistry. 2025 Jan 23;68(2):1824-1843. [Content Brief]
[2]. Hanl M, et al. Target Engagement Studies and Kinetic Live-Cell Degradation Assays Enable the Systematic Characterization of Histone Deacetylase 6 Degraders. ACS pharmacology & translational science. 2025 Sep 12;8(9):3074-3089. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)